HYPD

Company Overview — What Does EYENOVIA, INC. Do?

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York. EYENOVIA, INC. (HYPD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael M. Rowe and employs approximately 40 people. With a market capitalization of $28M, HYPD is one of the notable companies in the Healthcare sector.

EYENOVIA, INC. (HYPD) Stock Rating — Reduce (April 2026)

As of April 2026, EYENOVIA, INC. receives a Reduce rating with a composite score of 23.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.HYPD ranks #3,738 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, EYENOVIA, INC. ranks #626 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HYPD Stock Price and 52-Week Range

EYENOVIA, INC. (HYPD) currently trades at $3.57. The stock gained $0.30 (9.2%) in the most recent trading session. The 52-week high for HYPD is $17.18, which means the stock is currently trading -79.2% from its annual peak. The 52-week low is $0.85, putting the stock 320.0% above its annual trough. Recent trading volume was 411K shares, suggesting relatively thin trading activity.

Is HYPD Overvalued or Undervalued? — Valuation Analysis

EYENOVIA, INC. (HYPD) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 13.15x, compared to the Healthcare sector average of 23.63x — a discount of 44%. The price-to-book ratio stands at 0.85x, versus the sector average of 2.75x. The price-to-sales ratio is 109.68x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, HYPD trades at 1.64x EV/EBITDA, versus 6.34x for the sector.

At current multiples, EYENOVIA, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

EYENOVIA, INC. Profitability — ROE, Margins, and Quality Score

EYENOVIA, INC. (HYPD) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -32.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -26.0% versus the sector average of -33.1%.

On a margin basis, EYENOVIA, INC. reports gross margins of -2618.5%, compared to 71.5% for the sector. The operating margin is -156773.5% (sector: -66.1%). Net profit margin stands at -168960.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 1237.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HYPD Debt, Balance Sheet, and Financial Health

EYENOVIA, INC. has a debt-to-equity ratio of 26.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.68x, indicating strong short-term liquidity. Total debt on the balance sheet is $8M. Cash and equivalents stand at $8M.

HYPD has a beta of 1.87, meaning it is more volatile than the broader market — a $10,000 investment in HYPD would be expected to move 87.4% more than the S&P 500 on any given day. The stability factor score for EYENOVIA, INC. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

EYENOVIA, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, EYENOVIA, INC. reported revenue of $318,851 and earnings per share (EPS) of $-9.40. Net income for the quarter was $-13M. Gross margin was -2618.5%. Operating income came in at $-14M.

In FY 2025, EYENOVIA, INC. reported revenue of $813,455 and earnings per share (EPS) of $-9.40. Net income for the quarter was $-45M. Gross margin was 62.7%. Revenue grew 1318.8% year-over-year compared to FY 2024. Operating income came in at $-47M.

In Q3 2025, EYENOVIA, INC. reported revenue of $302,506 and earnings per share (EPS) of $0.26. Net income for the quarter was $7M. Gross margin was 100.0%. Revenue grew 18515.8% year-over-year compared to Q3 2024. Operating income came in at $4M.

In Q2 2025, EYENOVIA, INC. reported revenue of $0 and earnings per share (EPS) of $-2.50. Net income for the quarter was $-9M. Operating income came in at $-8M.

Over the past 8 quarters, EYENOVIA, INC. has demonstrated a growth trajectory, with revenue expanding from $22,625 to $318,851. Investors analyzing HYPD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HYPD Dividend Yield and Income Analysis

EYENOVIA, INC. (HYPD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HYPD Momentum and Technical Analysis Profile

EYENOVIA, INC. (HYPD) has a momentum factor score of 45/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 42/100 reflects moderate short selling activity.

HYPD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, EYENOVIA, INC. (HYPD) ranks #626 out of 838 stocks based on the Blank Capital composite score. This places HYPD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HYPD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HYPD vs S&P 500 (SPY) comparison to assess how EYENOVIA, INC. stacks up against the broader market across all factor dimensions.

HYPD Next Earnings Date

No upcoming earnings date has been announced for EYENOVIA, INC. (HYPD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HYPD? — Investment Thesis Summary

The quantitative profile for EYENOVIA, INC. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. High volatility (stability score 13/100) increases portfolio risk.

In summary, EYENOVIA, INC. (HYPD) earns a Reduce rating with a composite score of 23.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HYPD stock.

Related Resources for HYPD Investors

Explore more research and tools: HYPD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HYPD head-to-head with peers: HYPD vs AZN, HYPD vs SLGL, HYPD vs VMD.